听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览BONE MARROW TRANSPLANTATION期刊下所有文献
  • Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

    abstract::Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, ye...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-01179-5

    authors: Gupta AO,Jan Boelens J,Ebens CL,Kurtzberg J,Lund TC,Smith AR,Wagner JE,Wynn R,Blazar BR,Orchard PJ

    更新日期:2021-01-13 00:00:00

  • Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease.

    abstract::Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin D3 analog Calcipotriene (DOVONEX 0.005% cream) for acute skin GVHD i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01189-3

    authors: Wallace G,Khandelwal P,Myers KC,Perentesis EMR,Lane A,Teusink-Cross A,Smiley K,Davies SM,Jodele S

    更新日期:2021-01-08 00:00:00

  • Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.

    abstract::Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01005-y

    authors: Nagler A,Baron F,Labopin M,Polge E,Esteve J,Bazarbachi A,Brissot E,Bug G,Ciceri F,Giebel S,Gilleece MH,Gorin NC,Lanza F,Peric Z,Ruggeri A,Sanz J,Savani BN,Schmid C,Shouval R,Spyridonidis A,Versluis J,Mohty M

    更新日期:2021-01-01 00:00:00

  • Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT.

    abstract::We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105)...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01007-w

    authors: Gagelmann N,Eikema DJ,de Wreede LC,Rambaldi A,Iacobelli S,Koster L,Caillot D,Blaise D,Remémyi P,Bulabois CE,Passweg J,Leleu X,Zver S,Kobbe G,Ljungman P,Chevallier P,Ringhoffer M,Martin M,Salmenniemi U,Poiré X,Lenh

    更新日期:2021-01-01 00:00:00

  • Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

    abstract::In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01178-6

    authors: Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

    更新日期:2020-12-18 00:00:00

  • Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.

    abstract::In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01165-x

    authors: Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

    更新日期:2020-12-05 00:00:00

  • Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.

    abstract::The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01160-2

    authors: Song GY,Yoon DH,Suh C,Moon JH,Baek DW,Kim JS,Lee GW,Yi JH,Park Y,Jung KS,Kim SJ,Yang DH,Kim WS

    更新日期:2020-12-04 00:00:00

  • Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

    abstract::We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Po...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01156-y

    authors: Danylesko I,Shouval R,Shem-Tov N,Yerushalmi R,Jacoby E,Besser MJ,Shimoni A,Davidson T,Beider K,Mevorach D,Fried S,Nagler A,Avigdor A

    更新日期:2020-12-03 00:00:00

  • PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.

    abstract::Acute myeloid leukemia (AML) is an immune-susceptible malignancy, as demonstrated by its responsiveness to allogeneic stem cell transplantation (alloSCT). However, by employing inhibitory signaling pathways, including PD-1/PD-L1, leukemia cells suppress T cell-mediated immune attack. Notably, impressive clinical effic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0966-6

    authors: van Ens D,Mousset CM,Hutten TJA,van der Waart AB,Campillo-Davo D,van der Heijden S,Vodegel D,Fredrix H,Woestenenk R,Parga-Vidal L,Jansen JH,Schaap NPM,Lion E,Dolstra H,Hobo W

    更新日期:2020-12-01 00:00:00

  • Secondary oral cancer following hematopoietic cell transplantation.

    abstract::The aim of this retrospective study was to determine the incidence and the clinical outcome of secondary oral cancer (SOC) and to assess potential risk factors in a large cohort of patients (n = 908), who received allogeneic hemopoietic cell transplantation (HCT) either for a malignant (n = 733) or nonmalignant hemato...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01147-z

    authors: Santarone S,Natale A,Angelini S,Papalinetti G,Vaddinelli D,Di Bartolomeo A,Di Bartolomeo P

    更新日期:2020-11-24 00:00:00

  • Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS.

    abstract::The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01138-0

    authors: Mengling T,Rall G,Bernas SN,Astreou N,Bochert S,Boelk T,Buk D,Burkard K,Endert D,Gnant K,Hildebrand S,Köksaldi H,Petit I,Sauter J,Seitz S,Stolze J,Weber K,Weber M,Lange V,Pingel J,Platz A,Schäfer T,Schetelig J

    更新日期:2020-11-20 00:00:00

  • Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

    abstract::Stroke is an important complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, few studies have been published to analyzed the occurrence and prognosis of stroke after allo-HSCT. From January 2007 to December 2018 in Peking University People's Hospital, 6449 patients receiv...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0903-8

    authors: Cai X,Fu HX,Mo XD,Wang Y,Zhang YY,Wu J,Han W,Tang FF,Gui RY,Chen H,Chen Y,Zhao P,Yan CH,Wang JZ,Chen YH,Chang YJ,Xu LP,Liu KY,Huang XJ,Zhang XH

    更新日期:2020-11-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.

    abstract::Autologous hematopoietic stem cell transplantation (ASCT) is curative for a proportion of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). However, there is a small group of patients with high-risk of relapse after ASCT that might benefit from other approaches. We conducted a retrospective analysis on 12...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01075-y

    authors: Bento L,Boumendil A,Finel H,Khvedelidze I,Blaise D,Fegueux N,Castagna L,Forcade E,Chevallier P,Mordini N,Brice P,Deconinck E,Gramatzki M,Corradini P,Hunault M,Musso M,Tsoulkani A,Caballero D,Nati S,Montoto S,Sured

    更新日期:2020-10-12 00:00:00

  • Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.

    abstract::We should consider both the treatment effects and adverse effects of autologous hematopoietic stem cell transplantation (AHSCT) on multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Articles exploring the effect and safety of AHSCT in the treatment of MS and NMOSD and published before Decembe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0810-z

    authors: Zhang P,Liu B

    更新日期:2020-10-01 00:00:00

  • Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

    abstract::Serum concentrations of Anti-Müllerian hormone (AMH) and Inhibin B were used to assess potential fertility in survivors of childhood haematopoietic stem cell transplantation (HSCT) after three chemotherapy-conditioning regimens of differing intensity. Of 428 patients transplanted between 1990-2012 for leukaemia and im...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0866-9

    authors: Leiper A,Houwing M,Davies EG,Rao K,Burns S,Morris E,Laven J,van der Kooi AL,van den Heuvel Eibrink M,Nussey S

    更新日期:2020-10-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract::Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0857-x

    authors: Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期:2020-10-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract::On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-01068-x

    authors: Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期:2020-09-26 00:00:00

  • Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.

    abstract::Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01065-0

    authors: Sugita J,Kamimura T,Ishikawa T,Ota S,Eto T,Kuroha T,Miyazaki Y,Kumagai H,Matsuo K,Akashi K,Taniguchi S,Harada M,Teshima T

    更新日期:2020-09-24 00:00:00

  • Altered body composition in male long-term survivors of paediatric allogeneic haematopoietic stem cell transplantation: impact of conditioning regimen, chronic graft-versus-host disease and hypogonadism.

    abstract::Changes in body composition related to metabolic syndrome are frequent among survivors of haematopoietic stem cell transplantation (HSCT), but insights into predisposing factors are incomplete, and it is unknown to what degree these changes persist at long term. We cross-sectionally investigated body composition by du...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01038-3

    authors: Mejdahl Nielsen M,Mathiesen S,Suominen A,Sørensen K,Ifversen M,Mølgaard C,Lähteenmäki PM,Juul A,Jahnukainen K,Müller K

    更新日期:2020-09-02 00:00:00

  • Value and affordability of CAR T-cell therapy in the United States.

    abstract::In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-0956-8

    authors: Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

    更新日期:2020-09-01 00:00:00

  • Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.

    abstract::The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in controlling GVHD has been previously reported. We aim to study the safety and efficacy of the use of dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning regimen allo-HSCT in 270 patients w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0813-9

    authors: Salas MQ,Prem S,Atenafu EG,Datt Law A,Lam W,Al-Shaibani Z,Loach D,Kim DDH,Michelis FV,Lipton JH,Kumar R,Mattsson J,Viswabandya A

    更新日期:2020-09-01 00:00:00

  • Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.

    abstract::The aim of this study was to develop a comprehensive system for predicting non-relapse mortality after allogeneic hematopoietic cell transplantation (HCT) during first complete remission (CR) of acute myeloid leukemia (AML). After dividing 2344 eligible patients randomly into a training set and a validation set, we fi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01032-9

    authors: Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S

    更新日期:2020-08-14 00:00:00

  • Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors.

    abstract::The number of individuals undergoing unrelated cord blood transplantation (UCBT) has increased in recent years; however, information on prognostic factors is limited. We retrospectively analyzed data from 475 children and adolescents receiving UCBT with myeloablative conditioning for acute lymphoblastic leukemia (ALL)...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01019-6

    authors: Kawahara Y,Morimoto A,Inagaki J,Koh K,Noguchi M,Goto H,Yoshida N,Cho Y,Hori T,Hiwatari M,Kato K,Ogawa A,Hashii Y,Inoue M,Kato K,Atsuta Y,Kimura F,Kato M

    更新日期:2020-08-11 00:00:00

  • Improving cord blood typing with next-generation sequencing: impact of allele-level HLA and NIMA determination on their selection for transplantation.

    abstract::Allele-level HLA compatibility in cord blood transplantation, together with noninherited maternal antigen or NIMA matching, have been associated with better transplant outcomes. The aim of this work is to develop a cost-efficient high-resolution HLA typing strategy based on next-generation sequencing to improve the qu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0890-9

    authors: Enrich E,Vidal F,Corrales I,Campos E,Borràs N,Martorell L,Sánchez M,Querol S,Rudilla F

    更新日期:2020-08-01 00:00:00

  • Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W

    abstract::Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negativ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0951-0

    authors: Akahoshi Y,Nishiwaki S,Arai Y,Harada K,Najima Y,Kanda Y,Shono K,Ota S,Fukuda T,Uchida N,Shiratori S,Tanaka M,Tanaka J,Atsuta Y,Kako S

    更新日期:2020-07-01 00:00:00

  • Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.

    abstract::In the presence of effective treatment options for systemic light chain (AL) amyloidosis, autologous stem cell transplantation (ASCT) is sometimes deferred after stem cell collection. We designed this retrospective study to compare overall survival (OS) between patients who proceed directly to ASCT after stem cell col...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0964-8

    authors: Abdallah N,Sidana S,Dispenzieri A,Lacy M,Buadi F,Hayman S,Kapoor P,Leung N,Dingli D,Hwa YL,Lust J,Russell S,Gonsalves W,Go R,Hogan W,Kyle R,Rajkumar SV,Gertz M,Kumar S

    更新日期:2020-07-01 00:00:00

  • Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

    abstract::Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0741-8

    authors: Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

    更新日期:2020-05-01 00:00:00

  • Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.

    abstract::Reduced sexual function may have negative implications on health related quality of life among lymphoma survivors. A national cross-sectional study among long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplantation auto-SCT treated during 1987-2008 was conducted in 2012-2014. The curr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0745-4

    authors: Bersvendsen HS,Haugnes HS,Dahl AA,Fagerli UM,Fluge Ø,Holte H,Seland M,Wilsgaard T,Smeland KB,Kiserud CE

    更新日期:2020-05-01 00:00:00

  • Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

    abstract::We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-CY) and antithymocyte globulin (ATG), for unmanipulated peripheral blood stem cell (PBSC) transplants, in 80 patients with hematological malignancies. Patients in complete...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0726-7

    authors: Peric Z,Mohty R,Bastos J,Brissot E,Battipaglia G,Belhocine R,Sestili S,Giannotti F,Vekhoff A,Ledraa T,Legrand O,Lapusan S,Isnard F,Labopin M,Bonnin A,Mediavilla C,Rubio MT,Ruggeri A,Duléry R,Malard F,Mohty M

    更新日期:2020-04-01 00:00:00

  • Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

    abstract::Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0712-0

    authors: Fuji S,Oshima K,Ohashi K,Sawa M,Saito T,Eto T,Tanaka M,Onizuka M,Nakamae H,Shiratori S,Ozawa Y,Hidaka M,Nagamura-Inoue T,Tanaka H,Fukuda T,Ichinohe T,Atsuta Y,Ogata M

    更新日期:2020-04-01 00:00:00

  • Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.

    abstract::In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

    journal_title:Bone marrow transplantation

    pub_type: 已发布勘误

    doi:10.1038/s41409-019-0504-6

    authors: Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

    更新日期:2020-04-01 00:00:00

  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract::Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0298-y

    authors: Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期:2020-03-01 00:00:00

  • Correction to: Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Bone marrow transplantation

    pub_type: 已发布勘误

    doi:10.1038/s41409-019-0767-y

    authors: Moffet JR,Mahadeo KM,McArthur J,Hsing DD,Gertz SJ,Smith LS,Loomis A,Fitzgerald JC,Nitu ME,Duncan CN,Hall MW,Pinos EL,Tamburro RF,Simmons RA,Troy J,Cheifetz IM,Rowan CM,Investigators of the Pediatric Acute Lung Injury an

    更新日期:2020-02-01 00:00:00

  • Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc

    abstract::These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide recommendations for patient selection, transplant technique, follow-up and fut...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0684-0

    authors: Sharrack B,Saccardi R,Alexander T,Badoglio M,Burman J,Farge D,Greco R,Jessop H,Kazmi M,Kirgizov K,Labopin M,Mancardi G,Martin R,Moore J,Muraro PA,Rovira M,Sormani MP,Snowden JA,European Society for Blood and Marrow Tr

    更新日期:2020-02-01 00:00:00

  • Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children.

    abstract::Hemorrhagic cystitis (HC) is a debilitating complication following allogenic hematopoietic cell transplantation (HCT). HLA disparity and T-cell depletion have been implicated as risk factors for HC. However, reports on the incidence and risk factors for HC in ex vivo T-cell depleted haploidentical HCT (haploHCT) in ch...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0672-4

    authors: Jepsen C,Turkiewicz D,Ifversen M,Heilmann C,Toporski J,Dykes J,Mellgren K,Pronk CJ

    更新日期:2020-01-01 00:00:00

  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

    abstract::Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0660-8

    authors: Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

    更新日期:2020-01-01 00:00:00

  • Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant

    abstract::On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0451-2

    authors: Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

    更新日期:2019-11-01 00:00:00

  • Safety and efficacy of fresh whole blood donor lymphocyte infusion in children.

    abstract::Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/s41409-019-0580-7

    authors: Swaminathan VV,Uppuluri R,Patel S,Sivashankaran M,Ravichandran N,Ramanan KM,Ramakrishnan B,Vaidhyanathan L,Raj R

    更新日期:2019-11-01 00:00:00

  • Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

    abstract::While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0500-x

    authors: Granata A,Fürst S,Bramanti S,Legrand F,Sarina B,Harbi S,De Philippis C,Faucher C,Chabannon C,Lemarie C,Calmels B,Mariotti J,Maisano V,Weiller PJ,Mokart D,Vey N,Bouabdallah R,Castagna L,Blaise D,Devillier R

    更新日期:2019-11-01 00:00:00

874 条记录 1/22 页 « 12345678...2122 »